ArticleNPJ Parkinson's disease2025
Spatial variations and precise location of substantia nigra hyperechogenicity in Parkinson's disease using TCS-MR fusion imaging.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Striatal hyperechogenicity as an ultrasound imaging marker for prodromal X-linked dystonia-parkinsonism.NPJ Parkinson's disease · 2026Article
- A stacked multi-classifier for multi-modal data fusion in transcranial sonography-based Parkinson's disease assessment.NPJ Parkinson's disease · 2026Article
- A nomogram combined substantia nigra hyperechogenicity with third ventricular width assessed by transcranial sonography in prediction Parkinson's disease-related cognitive impairment.BMC medical imaging · 2026Article
- Super-resolution ultrasound imaging indirectly reveals neurovascular uncoupling in substantia nigra of a Parkinson's disease model.NPJ Parkinson's disease · 2026Article
- Diagnostic accuracy of transcranial sonography-magnetic resonance fusion imaging for Parkinson's disease versus multiple system atrophy-Parkinsonian type.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Substantia nigra hyperechogenicity (SNH) assessed by transcranial sonography (TCS) is a neuroimaging biomarker of Parkinson's disease (PD), but its actual location and spatial changes are poorly understood. We aimed to evaluate the location and spatial progression of SNH in PD utilizing TCS-MR fusion imaging. This prospective study enrolled eighty-four PD patients and sixty-two controls. The plane with the largest area of red nucleus, the plane with the largest area of SNH, and the plane where the red nucleus is just out of view were selected and segmented, respectively, and echogenicity indices were calculated. SNH could present in SN, dorsal band of SN, red nucleus, and ventral tegmental area, and had two orientations. In the left midbrain, the anterior-posterior orientation had longer disease duration, larger SNH area, and higher Hoehn-Yahr stage than medial-lateral orientation. The anterior-posterior orientation and accumulation in various nuclei of SNH may serve as promising neuroimaging markers for PD progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.